Method of treating lower urinary tract disorders
First Claim
1. A method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment, wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising administering to said subject:
- a) a first amount of an α
2δ
subunit calcium channel ligand; and
b) a second amount of a substituted aminomethyl-phenyl-cyclohexane derivative, wherein the first and second amounts together comprise a therapeutically effective amount.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis comprising coadministering to said subject a first amount of an α2δ subunit calcium channel ligand and a second amount of a substituted aminomethyl-phenyl-cyclohexane derivative, wherein the first and second amounts together comprise a therapeutically effective amount. The coadministration of a first amount of an α2δ subunit calcium channel ligand and a second amount of a substituted aminomethyl-phenyl-cyclohexane derivative can result in an enhanced or synergistic therapeutic effect, wherein the combined effect is greater than the additive effect resulting from separate administration of the first amount of the α2δ subunit calcium channel ligand and the second amount of the substituted aminomethyl-phenyl-cyclohexane derivative.
52 Citations
61 Claims
-
1. A method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment, wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising administering to said subject:
-
a) a first amount of an α
2δ
subunit calcium channel ligand; and
b) a second amount of a substituted aminomethyl-phenyl-cyclohexane derivative, wherein the first and second amounts together comprise a therapeutically effective amount. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)
-
-
23. A method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment, wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising administering to said subject:
-
a) a first amount of a GABA analog selected from the group consisting of;
gabapentin, pregabalin or a combination thereof; and
b) a second amount of tramadol hydrochloride, wherein the first and second amounts together comprise a therapeutically effective amount. - View Dependent Claims (24, 25, 26, 27, 28, 29)
-
-
30. A method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment, wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising administering to said subject:
-
a) a first amount of an α
2δ
subunit calcium channel ligand; and
b) a second amount of a substituted aminomethyl-phenyl-cyclohexane derivative represented by structural Formula III and enantiomers and mixtures thereof;
or pharmaceutically acceptable salts, solvates and hydrates thereof, wherein the first and second amounts together comprise a therapeutically effective amount. - View Dependent Claims (31, 32, 33, 34, 35, 36, 37, 38, 39, 40)
-
-
41. A method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment, wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising administering to said subject:
-
a) a first amount of an α
2δ
subunit calcium channel ligand; and
b) a second amount of a substituted aminomethyl-phenyl-cyclohexane derivative selected from the group consisting of (+/−
)O-desmethyltramadol, (+)O-desmethyltramadol, (−
)O-desmethyltramadol, (+/−
)O-desmethyl-N-mono-desmethyl-tramadol, (+)O-desmethyl-N-mono-desmethyl-tramadol, (−
) O-desmethyl-N-mono-desmethyl-tramadol and a combination thereof. - View Dependent Claims (42, 43, 44, 45, 46, 47, 48)
-
-
59. A kit comprising a sub-therapeutic dose of a compound which is an α
-
2δ
subunit calcium channel ligand, instructions for use with a compound which is a substituted aminomethyl-phenyl-cyclohexane derivative and optionally a device for administering the compounds.
-
2δ
-
60. A kit comprising a sub-therapeutic dose of a compound which is a substituted aminomethyl-phenyl-cyclohexane derivative, instructions for use with a compound which is an α
-
2δ
subunit calcium channel ligand and optionally a device for administering the compounds.
-
2δ
-
61. A kit comprising a first compound which is an α
-
2δ
subunit calcium channel ligand, a second compound which is a substituted aminomethyl-phenyl-cyclohexane derivative and instructions for administering the first and second compounds and optionally a device for administering the compounds, wherein at least one of said first or second compound is present in a sub-therapeutic dose.
-
2δ
Specification